SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- New York Fashion Week Hits the Runway as Colors Pop

TOP HEADLINES

» Markets | Economy | Companies

- Stocks Looking Past Europe for a New Driver of the Rally

PHARMA'S MARKET VIDEO

» More

Wall Street Protests 29 Apr 2010
Following a big demonstration in favor of financial regulation right outside the NYSE, with CNBC's Mike Huckman.
March on Wall Street 29 Apr 2010
Main Street takes to Wall Street today with thousands of union community activists marching to make the big banks pay, with CNBC's Mike Huckman.
Mike Huckman: Reporter's Reporter 29 Apr 2010
Original air date, June 26, 2002.
SBUX Beats the Street 21 Apr 2010
CNBC's Mike Huckman has Starbucks' earnings breakdown.

The Orange Squeeze on Dimon

16 Apr 2010

Some students at Syracuse University have a different idea rather than having JPMorgan's chairman/CEO Jamie Dimon deliver this year's commencement speech, reports CNBC's Mike Huckman.

Nasdaq Outperforms 14 Apr 2010
The Nasdaq easily outperforming the other major indexes today, with CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

Pharma's Market

Text Size

Apr.03

4:08 PM ET

Friday, 3 Apr 2009

Dendreon's Freaky Friday

Posted By:Mike Huckman

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Dendreon Corp

CNBC.com
I'm not really enjoying my "day off" so far here in rather gloomy, cool L.A. as I've been kept pretty busy trying to chase down the Dendreon [DNDN Loading... () ] story.

The shares are hitting a new intra-day high on heavy volume on word that the American Urological Association is saving a seat at the table for DNDN at its annual meeting the end of this month.

The stock started moving this morning when that information was posted on the AUA's website. I started getting tweets on Twitter and emails from Dendreonians calling the news, volume and movement to my attention.

I ran it down with calls to Dendreon, the AUA and Dendreon's outside PR. Got quick calls back from all of them, but DNDN CFO Greg Shiffman was the first to get back to me.

He said he didn't see why this was creating so much buzz.

Yes, he confirmed, AUA has given the company a "placeholder" to present the highly anticipated Provenge data in a prestigious "late breaker" session if they're ready in time for the event. But that will only happen in the event the clinical trial results are available by then. Shiffman pointed out that the company has been saying the data were expected sometime in April.

Shiffman also told me Dendreon does not have a similar placeholder at the American Society of Clinical Oncology meeting which takes place about a month later.

Interestingly, the placeholder info seems to have been taken off the AUA website. I have a call into the organization about that and I will update the blog if/when I hear back. I suspect it was at the company's request given the frenzy it triggered.

Never a dull moment.

UPDATE: A DNDN spokesperson says the company did not request that the AUA remove the info from its website. An AUA spokesperson says it was taken down by mistake and is now back up.

Check this out: